Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis
NCT ID: NCT00628797
Last Updated: 2017-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
9 participants
INTERVENTIONAL
2008-02-29
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
UVA-1 for Treatment of Skin Tightening and Improvement of Hand Function in Scleroderma
NCT04875078
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
NCT04922736
Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma
NCT02002897
Optical Coherence Tomography Imaging in Systemic Sclerosis
NCT04532151
The Influence of Extracorporeal Photopheresis on Skin Sclerosis
NCT04752397
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A UVA1 B no UVA1
half body irradiation with random allocation right and left; after three months of treatment treatment of both sides
UVA1
60 J/cm2 at least 36 tx
A UVA1
UVA1
intraindividual half body irradiation
UVA1
60 J/cm2 at least 36 tx
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UVA1
intraindividual half body irradiation
UVA1
60 J/cm2 at least 36 tx
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* skin fibrosis at least involving the distal third of the lower arm
Exclusion Criteria
* recent UV therapy
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Nicolas Hunzelmann
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nicolas Hunzelmann
Prof. Dr. N. Hunzelmann
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicolas Hunzelmann
Role: PRINCIPAL_INVESTIGATOR
University of Cologne, Dept. of Dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Tuebingen, Dept. of Dermatology
Tübingen, Baden-Wurttemberg, Germany
University of Cologne, Dept. of Dermatology
Cologne, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-200
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.